Welcome to our dedicated page for Tonix Pharmaceuticals Holding SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tonix Pharmaceuticals Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tonix Pharmaceuticals Holding's regulatory disclosures and financial reporting.
Tonix Pharmaceuticals Holding Corp. is asking shareholders to approve several key items at its 2026 virtual annual meeting. Investors will vote on electing nine directors, ratifying PwC as the new independent auditor, authorizing a flexible reverse stock split, and adopting a new 2026 stock incentive plan.
The Board seeks authority to implement one or more reverse stock splits over two years, at ratios between 1:2 and 1:250, to help maintain Nasdaq listing standards tied to minimum bid price. Shareholders of record on March 19, 2026, when 13,405,401 common shares were outstanding, may vote online or by proxy.
Tonix Pharmaceuticals Holding Corp: The Vanguard Group filed an amendment stating it currently reports zero beneficial ownership of Tonix common stock. The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries/divisions to report holdings separately and says Vanguard no longer is deemed to beneficially own securities reported by those entities. The filing lists Amount beneficially owned: 0 and Percent of class: 0%, and is signed by Ashley Grim on 03/27/2026.
Tonix Pharmaceuticals Holding Corp. is advancing its migraine pipeline with the first participant dosed in a Phase 1 investigator-initiated study of TNX-1900, an intranasal potentiated oxytocin candidate. The trial uses a trigeminal neurovascular reactivity model, measuring forehead blood flow responses to capsaicin and electrical stimulation in healthy female volunteers.
The study is led and sponsored by Professor Antoinette Maassen van den Brink at Erasmus University Medical Center under a collaborative research agreement. TNX-1900 targets oxytocin receptors in the trigeminal system to block CGRP release, offering a mechanism distinct from triptans and CGRP inhibitors and aiming at non-opioid treatment options for migraine and other craniofacial pain conditions.
The Board of Tonix Pharmaceuticals Holding Corp. has scheduled a virtual Annual Meeting for May 7, 2026 to vote on: election of nine directors; ratification of PwC as independent auditors; a proposal authorizing the Board to implement one or more reverse stock splits at ratios between 1:2 and 1:250; and approval of the 2026 Stock Incentive Plan. Only shareholders of record at the close of business on March 19, 2026 may vote. The company reported 13,405,401 shares of common stock outstanding as of the Record Date. The Board recommends a vote FOR all proposals, and preliminary voting results will be announced at the meeting with final results filed on Form 8-K.
Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman bought 15,000 shares of common stock in an open-market transaction at $14.89 per share through an IRA account.
After this purchase, he held 15,001 shares indirectly via the IRA, 4,005 shares directly, and 1 share indirectly through Lederman & Co., where he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. changed its independent auditor, dismissing EisnerAmper LLP and appointing PricewaterhouseCoopers LLP for the 2026 audit, with Audit Committee approval. The company states the dismissal was not related to disagreements over accounting, disclosure, or audit scope.
EisnerAmper’s reports for 2024 and 2025 were clean except for an explanatory paragraph highlighting continuing losses and negative operating cash flows that raised substantial doubt about Tonix’s ability to continue as a going concern. Previously disclosed material weaknesses in internal control over financial reporting were remediated by year-end 2024 and did not require financial statement restatements.
Tonix Pharmaceuticals reported fourth quarter and full year 2025 results, highlighted by the November 17 U.S. launch of TONMYA for fibromyalgia. Net product revenue for 2025 was about $13.1M, up from $10.1M in 2024, including roughly $1.4M from TONMYA.
Cash and cash equivalents were approximately $207.6M as of December 31, 2025, compared with $98.8M a year earlier, helped by a $20.0M registered direct offering and ATM usage. The company posted a 2025 net loss available to common stockholders of about $124.0M, versus $130.0M in 2024.
Fourth quarter 2025 net product revenue was roughly $5.4M, up from $2.6M in the prior-year quarter, while the net loss available to common stockholders was $46.9M. Management cites ongoing investment in TONMYA commercialization and a broad CNS, infectious disease, immunology, and rare disease pipeline, and believes existing cash will fund operations into the first quarter of 2027.
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company focused on central nervous system disorders, immunology, infectious diseases, and rare diseases. In August 2025 it received FDA approval for TONMYA, a bedtime, non-opioid sublingual cyclobenzaprine tablet for fibromyalgia in adults, and launched it in November 2025.
The company also markets two acute migraine products, Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray), and is advancing a broad pipeline including TNX‑102 SL for major depressive disorder and acute stress disorder, TNX‑4800 for Lyme disease prophylaxis, TNX‑1500 for kidney transplant rejection and autoimmune conditions, TNX‑1300 for cocaine intoxication, TNX‑1900 and TNX‑2900 for oxytocin‑based CNS and rare disease indications, TNX‑801 as a live‑virus smallpox/mpox vaccine candidate, and TNX‑4200 and TNX‑4900 for antiviral and neuropathic pain indications.
Tonix Pharmaceuticals Holding Corp. reported new post hoc Phase 3 data for TONMYA (cyclobenzaprine HCl sublingual tablets), its FDA‑approved fibromyalgia treatment, presented at the 8th International Congress on Controversies in Fibromyalgia.
In the 14‑week RESILIENT study of 457 adults, TONMYA produced rapid pain relief versus placebo as early as Day 2, with statistically significant pain reductions each week through Week 14 and a least‑squares mean treatment difference of -0.65 on numeric rating scale pain scores. All key secondary endpoints favored TONMYA, and discontinuations due to adverse events were 6.1% versus 3.5% with placebo, mainly mild, transient oral cavity reactions.
A pooled analysis of 959 participants from the RELIEF and RESILIENT trials showed a number needed to treat of 7 for ≥30% pain reduction and a number needed to harm of 26 for discontinuation due to adverse events, yielding a likelihood to be helped or harmed of 3.7. The company highlights TONMYA as the first new prescription medicine for fibromyalgia in more than 15 years and provides extensive prescribing, safety, and use‑in‑population information.